The Impact of bariatric surgery for the management of type 2 diabetes mellitus

Mokhlef Khalefah Alanazi
Fahad Faris Almanjam

Abstract:

Diabetes is the big problem of this developing world. In this review we discuss bariatric surgery types to better understand the mechanism of surgery impact and its effectiveness. Detailed searches of the literature were performed on MEDLINE, EMBASE, SCOPUS, with the timeframe up to May, 2018. Conventional bariatric treatments are being used worldwide to deal with Type 2 diabetes in association with obesity, and progressively among less obese or just overweight patients. There is no solitary or standard procedure for managing of morbidly obese diabetic patients. Taking into consideration the complexity of obesity comorbid with T2DM, extra prevalent adjustments will require to occur through integrated changes in way of life, public policy, and personal enterprise to advertise healthy and balanced preventive steps and effective treatment options, hopefully leading to continual reductions in new and existing instances of T2DM.

Introduction:

Type 2 diabetes mellitus (T2DM) and morbid obesity are problems representing increasing public wellness hazards. They are related to substantial morbidity and death, and in spite of lifestyle adjustments and medical assistance, glycemic control stays difficult to attain in obese diabetic patients [1].Bariatric surgery has up until now shown high efficacy in attaining T2DM lasting

remission and sturdy weight loss [2-4], leading the International Diabetes Federation (IDF) and the American Diabetes Association (ADA) to recommend bariatric surgery as a reliable therapy method in overweight patients with T2DM [5,6].Various laparoscopic bariatric treatments have been checked out to deal with T2DM obese patients, with superb lead to regards to weight reduction and glycemic control reported for both the biliopancreatic diversion with or without the duodenal switch (BPD/BPD-DS) and the Roux-en-Y gastric bypass (RYGBP) [2,7]. On the other hand, limiting treatments such as the sleeve gastrectomy (SG) and the laparoscopic flexible gastric banding (LAGB), although effective on fat burning, seem to give various results on T2DM remission. In fact, while the SG provides an end result that, in some studies, approaches RYGBP [8-10], the LAGB appears to determine a lower influence on sugar homeostasis, accomplishing debatable outcomes [2,11,12]. The mini gastric bypass or one anastomosis gastric bypass (MGB/OAGB) come from by Rutledge in 1997 [13] is an emerging technique consisting in a simplified variation of the timeless RYGBP. When described, MGB/ OAGB increased severe criticism, repeated in an extra current discussion [14, 15], but despite such doubtful position, different writers have reported superb cause terms of weight management and resolution of obesity-related comorbidities [16], consisting of T2DM [17] and ladies obesity-related infertility [18].To date, MGB/OAGB has gotten to the condition of a basic bariatric treatment in Italy (http://www.sicob.org) and several other nations [19], providing outstanding outcomes even in the long-term [20].A recent survey recommended by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) has reported MGB/OAGB being the most often performed treatment following the more well-known laparoscopic RYGBP, SG, and LAGB in Europe and Asia/Pacific area [21].

Diabetes is the big problem of this developing world. In this review we discuss bariatric surgery types to better understand the mechanism of surgery impact and its effectiveness.

Methodology:

Detailed searches of the literature were performed on MEDLINE, EMBASE, SCOPUS, with the timeframe up to May, 2018, for studies that discussing bariatric surgery in diabetic patients. We limited our search to only English language published studies with human subjects.

Discussion:

- **Bariatric Surgery and Diabetes**
- **Types of Procedures and Patients**

Improvement of T2DM, consisting of its remission, as a result of bariatric surgery has been identified for even more than a decade [22].Not all bariatric treatments are the same. Limiting procedures, malabsorptive treatments, or a mix of both treatments each have their very own specific threats and advantages (Table 1) [23].What procedure to pick pertains to numerous elements, regardless of insurance coverage. The patient's choice, the treatment with which the surgeon is most comfortable, just what makes good sense medically (such as just how much weight the patient should shed), comorbid conditions, age, and how long a patient has had T2DM should all be taken into consideration when selecting the ideal procedure. More recent surgical strategies and technologies are advancing swiftly. As an example, an endoluminal sleeve put endoscopically imitates the Roux-en-Y gastric bypass (RYGB) and has revealed appealing results as a less-invasive method for weight management in patients with T2DM [24].It takes around 30

minutes to place and develops a barrier over the duodenum and first part of the jejunum. The device likely changes the incretin and digestive tract hormones (enteroinsular milieu) of the body, resulting in weight reduction and enhanced glucose homeostasis [25].The duty of incretins and T2DM has been evaluated elsewhere [26].

Table 1. Common Bariatric Procedures: Risks and Benefits [23].

Restrictive Laparoscopic adjustable gastric banding Vertical banded gastroplasty Silastic ring gastroplasty Roux-en-Y gastric bypass	**Benefits** Weight loss with improved glycemic responses Improved insulin resistance Improvement in weight related comorbid conditions Most procedures are reversible (no permanent anatomical change) -Most procedures can be done laparoscopically **Risks** Typical risks for a surgical procedure (eg, infection, anesthesia) Bowel obstruction or leakage from anastomosis -Nutritional deficiencies (macro- and micronutrients) Possible need to use some nutritional supplements Nausea/vomiting/constipation/gallbladder problems Low risk for revision of procedure
Malabsorptive Roux-en-Y gastric bypass Biliopancreatic diversion (with or without duodenal switch) Duodenal switch Endoluminal sleeve	**Benefits** Results are more pronounced than RPs Weight loss . RP with improved glycemic responses Improvement in insulin resistance . RP Improvement in weight-related comorbid conditions Some procedures can be done laparoscopically **Risks** Typical risks for a surgical procedure (eg, infection, anesthesia) Bowel obstruction/leakage more likely vs RP -Nutritional deficiencies (macro- and micronutrients . RP) Lifelong need to use nutritional supplements Nausea/vomiting/diarrhea Higher risk for revision of procedure vs RP

There are 3 main categories of bariatric surgery that may be used to help with weight loss: restrictive procedures, malabsorptive procedures, or a combination of both procedures. Figures 1 and 2 depict the common procedures of each category. As mentioned, other procedures are currently under investigation, including the endoscopic duodenal-jejunal bypass sleeve, which is a nonsurgical method for weight loss in the morbidly obese[25]. There are 2 basic types of procedures that are a combination of both restrictive and malabsorptive mechanisms: the biliopancreatic diversion (BPD) and the heretofore gold standard, RYGB.



Figure 1A–C. Common restrictive techniques.A) Vertical banded gastroplasty; B) Adjustable gastric banding; C) Roux-en-Y gastric bypass. Reproduced with permission from Gastroenterology[29].



Figure 2A–C. Common malabsorptive techniques.A) Jejunoileal bypass; B) Biliopancreatic diversion; C) Duodenal switch. Reproduced with permission from Gastroenterology [29].

- **Which Procedure for Which Patient?**

Malabsorptive treatments (or a combination of both malabsorptive/restrictive treatments) show up to be more efficacious compared to limiting treatments. Table 2 sums up the dangers and the advantages of restrictive and malabsorptive treatments. Although the devices are not completely understood, it is clear that glycemic control is not asserted on weight-loss alone, as blood sugar level appropriate within hrs operatively and continuously improve for days to several weeks after that. This is long before any type of significant fat burning occurs, with greater than three-fourths of patients with T2DM experiencing full resolution of diabetes mellitus (Table 3) [27]. Thus, BPD appears to have the best influence with respect to modifications in the enteroinsular axis, glycemic control, as well weight reduction, adhered to by RYGB and laparoscopically helped gastric bypass (LAGB). On the whole, limiting procedures are less efficient compared to malabsorptive treatments (open or laparoscopic), however still have superb efficacy relative to fat burning and glycemic control. Based on operative/postoperative death information, LAGB is the safest bariatric surgery procedure [27].Table 2 shows the effect of various bariatric surgery procedures on different scientific specifications of rate of interest.

Because there are no head-to-head randomized regulated tests in severely obese patients that compare any one of these surgeries (eg, upright banding vs RYGB), it would be hasty to suggest a specific surgery over another for a specific at-risk populace. Patient option is determined by even more variables compared to the treatment itself. Pre-bariatric surgical patient selection is based on the same criteria utilized for other basic surgical procedures. Comorbid problems that position a patient at prospective danger have to be evaluated. Making use of BMI as the primary

requirement for bariatric surgery has been highly slammed [28] for several reasons, and existing guidelines do not permit surgical prospects with BMIs of, 35 kg/m^2.

Table 2. Clinical Impact of Select Bariatric Surgeries .Results of Different Types of Bariatric Surgery [27]

Result	Malabsorptive (BPD)	Restrictive (LAGB, VBG)	Combined (RYGB)
Excess weight loss, %	72	48–68	62
Resolution of comorbid conditions, %			
Type 2 diabetes mellitus	98	48–72	84
Hypertension	81	28–73	75
Dyslipidemia improved	100	71–81	94
Operative mortality rate, %	1.10	0.1	0.5

Mean values from a meta-analysis of 22 094 patients.
Abbreviations: BPD, biliopancreatic diversion; LAGB, laparoscopic adjustable gastric banding; RYGB, Roux-en-Y gastric bypass; VBG, vertical banded gastroplasty.

- **Mechanisms of metabolic improvement**

Bariatric surgery is a very effective means of inducing diabetes remission in very obese patients with T2DM [31].Diabetes remission results from improvements in both insulin resistance and C-cell disorder. Better insulin action on glucose metabolic process soothes secretory pressure on the C-cell, causing minimized insulin output [32],[33].However, substantial improvements in dynamic C-cell responses could likewise play a duty. This could be the outcome of decreased glucotoxicity and/or certain incretin results favouring C-cell function. By rank order of increasing efficiency in glucose control, the most common surgeries go from the solely limiting to the mainly limiting and to the primarily malabsorptive, thus paralleling their weight-reducing impacts. The devices in charge of glycaemic enhancement and settlement/ remission of diabetes after bariatric surgery likewise rely on the type of operation made use of. Calorie constraint and weight loss are the dominant systems of improved glucose metabolic process when entirely restrictive techniques are applied [38],[39].The previous appears to represent the early post-surgical recuperation of insulin sensitivity and secretory dynamics, while the latter is the last

determinant of outcome once weight and caloric equilibrium have supported [32],[33].In general, when assessing the result of only limiting treatments, the continual renovation of glucose control is straight proportional to the last amount of weight management. Nevertheless, despite RYGB, the percentage of weight lost is a predictive variable of diabetic issues remission [34]. When food transit is surgically modified, modifications in the pattern of gastrointestinal hormone release might sustain very early adjustment of C-cell function, but this is unlikely to earn a significant payment to insulin activity. Weight-independent antidiabetic results with RYGB appear from the rapid resolution of T2DM (prior to weight loss takes place), the greater enhancement of glucose homoeostasis after RYGB compared to after equivalent weight loss by various other means and the periodic growth of very-late-onset pancreatic C-cell hyperfunctioning. Several systems most likely mediate the direct antidiabetic influence of RYGB, including: enhanced nutrient stimulation of L-cell peptides [for instance, glucagon-like peptide-1 (GLP-1)] from the reduced intestine (' hindgut theory'); the fascinating, but yet uncharacterized, experiences associated to exemption of the upper intestine from contact with consumed nutrients (' foregut hypothesis'); jeopardized ghrelin secretion; and more than likely various other impacts that have yet to be determined [30], [35], [36].Undoubtedly, a duty for glucagon or gut-derived glucagonotropic signalling as alleged diabetogenic signs from the foregut has been recently suggested [37].Study created to prioritize these mechanisms and identify potential additional systems guarantees in order to help in the optimalization of surgical design (see Perspectives below) and may also reveal unique pharmaceutical targets for antidiabetes medication treatments [36].

- **Clinical advantages**

The dataset of a current systematic review and metaanalysis included 621 research studies with 888 treatment arms and 135,246 patients; of these studies, 103 therapy arms, including 3188

patients, reported intention of diabetes- that is, resolution of the clinical and laboratory manifestations of T2DM [38].Additionally, 19 research studies with 43 treatment arms and 11,175 patients reported both weight-loss and diabetes mellitus resolution in 4,070 diabetic patients. At standard, the patients'mean age was 40.2 years, BMI was 47.9 kg/m, 80% were women and 10.5% had actually undertaken previous bariatric treatments. Meta-analysis showed an overall loss of 38.5 kg or 56% of excess body weight. Also, 78% of the diabetic patients enjoyed total resolution of their condition, while diabetes was improved or fixed in almost 87%. Weight loss and diabetes resolution were biggest for patients undergoing BPDS, complied with by RYGB, and was lowest with LAGB. Insulin levels declined significantly postoperatively, as did glycated haemoglobin (HbA1c) and fasting glucose values. Weight and diabetes specifications showed little differences within 2 years, or after 2 or more years, of follow-up. The final thought was that the clinical and laboratory manifestations of T2DM were resolved or improved in the huge majority of patients after bariatric surgery, and these responses are extra obvious with procedures that resulted in a better portion of excess weight-loss preserved for 2 or even more years.

Besides the impact on glucose control, bariatric surgery additionally results in substantial enhancement of cardio risk variables, especially those linked with the metabolic syndrome, consisting of inflammation pens [39].The prospective Swedish Obese Subjects (SOS) research study confirmed that bariatric surgery considerably improves glucose, lipid and blood pressure management in surgically contrasted with medically dealt with obese individuals [40].Recently, the 10.9-year follow-up of the SOS research study reported a significant 30% threat reduction in general mortality in 2,010 obese patients (7.4% with T2DM) that had undertaken bariatric surgery [41].Similarly, in a retrospective US cohort of 7,925 surgical patients primarily managed

with RYGB, mortality from any type of cause was substantially 40% below in 7,925 non-surgical obese patients [42].However, mortality information for a details diabetic associate are scanty. In a very early retrospective analysis of 2 groups of obese diabetic person patients, the mortality rate (including perioperative deaths) in the control medical group was 28% after 6.2 years contrasted with only 9% in the RYGB surgical group after 9 years. For every year of follow-up, patients in the control group had a 4.5% threat of dying vs 1.0% for those in the surgical team. The enhancement in mortality with surgery was mainly as a result of a decline in the variety of cardiovascular fatalities [43].Lately, a systematic review wrapped up that bariatric surgery seems a clinically and cost-effective treatment for moderate-to-severely obese people compared to non-surgical treatments [44].However, uncertainties linger and more study is called for. In particular, new research should check out the resolution and/or growth of T2DM and, more crucial, the duration of T2DM remission, so that the potential benefits of early treatment could be better analyzed.

Conclusion:

Various researches show that bariatric surgery for obesity could lead to considerable and sustained weight loss. Dangers of bariatric surgery are easily measurable and could be separated into fatality and postoperative early and late complications. The operative death of bariatric surgery depends upon many varied aspects-- surgeon- and facility-related, patient-related, and procedure-related. Operative selection algorithms have tried to match particular patients with a particular procedure in order to, to name a few aspects, minimize operative death.

Diabetes is highly related to raised morbidity and mortality complying with bariatric surgery. On the other hand, the benefits of bariatric operations in morbidly obese diabetic patients can barely be exaggerated. The variety of complications after weight-loss surgery relies on the particular treatment. Restrictive methods (LAGB, VBG, SG) seldom influence bowel work and do not create malabsorption. Operations that produce malabsorption can create a variety of nutritional deficiencies. Conventional bariatric treatments are being used worldwide to deal with Type 2 diabetes in association with obesity, and progressively among less obese or just overweight patients. There is no solitary or standard procedure for managing of morbidly obese diabetic patients. Taking into consideration the complexity of obesity comorbid with T2DM, extra prevalent adjustments will require to occur through integrated changes in way of life, public policy, and personal enterprise to advertise healthy and balanced preventive steps and effective treatment options, hopefully leading to continual reductions in new and existing instances of T2DM.

Reference:

1. Deitel M. A brief history of the surgery for obesity to the present, with an overview of nutritional implications. J Am Coll Nutr. 2013;32(2):136–42.
2. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.

3. Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36. OBES SURG
4. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.
5. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery for diabetes: the International Diabetes Federation takes a position. J Diabetes. 2011;3(4):261–4.
6. The American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36 Suppl 1:S11–66.
7. Hedberg J, Sundström J, Sundbom M. Duodenal switch versus Rouxen-Y gastric bypass for morbid obesity: systematic review and metaanalysis of weight results, diabetes resolution and early complications in single-centre comparisons. Obes Rev. 2014;15(7):555–63.
8. Yip S, Plank LD, Murphy R. Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes. Obes Surg. 2013;23(12):1994–2003.
9. Pham S, Gancel A, Scotte M, et al. Comparison of the effectiveness of four bariatric surgery procedures in obese patients with type 2 diabetes: a retrospective study. J Obes. 2014;2014:638203. doi:10. 1155/2014/638203.
10. Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391–9.
11. Panunzi S, De Gaetano A, Carnicelli A, et al. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg. 2015;261(3):459–67.
12. Yu J, Zhou X, Li L, et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg. 2015;25(1):143–58.
13. Rutledge R. The mini-gastric bypass: experience with the first 1, 274 cases. Obes Surg. 2001;11:276–80.
14. Mahawar KK, Carr WR, Balupuri S, et al. Controversy surrounding ‘mini’ gastric bypass. Obes Surg. 2014;24(2):324–33.
15. Musella M, Milone M. Still Bcontroversies^ about the mini gastric bypass? Obes Surg. 2014;24(4):643–4.
16. Kular KS, Manchanda N, Rutledge R. A 6-year experience with 1, 054 mini-gastric bypasses—first study from Indian subcontinent. Obes Surg. 2014;24(9):1430–5.
17. Milone M, Di Minno MN, Leongito M, et al. Bariatric surgery and diabetes remission: sleeve gastrectomy or mini-gastric bypass? World J Gastroenterol. 2013;19(39):6590–7.
18. Musella M, Milone M, Bellini M, et al. Effect of bariatric surgery on obesity-related infertility. Surg Obes Relat Dis. 2012;8(4):445–9.
19. Lee WJ, Lin YH. Single-anastomosis gastric bypass (SAGB): appraisal of clinical evidence. Obes Surg. 2014;24(10):1749–56.

20. Bruzzi M, Rau C, Voron T, et al. Single anastomosis or mini-gastric bypass: long-term results and quality of life after a 5-year follow-up. Surg Obes Relat Dis. 2015;11(2):321–6.
21. Angrisani L, Santonicola A, Iovino P, et al. (2015) Bariatric surgery worldwide 2013. Obes Surg (in press).
22. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–350.
23. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006;91(11):4223–4231.
24. Rodriguez-Grunert L, Galvao Neto GP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–59.
25. Gersin KS, Keller JE, Stefanidis D, et al. Duodenal-jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov. 2007;14(4):275–278.
26. Giard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab. 2008;34(6 pt 1):550–559.
27. Buchwald H, Braunwald E, Pories FW, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–1737.
28. Dixon JB. Referral for a bariatric surgical consultation: it is time to set a standard of care. Obes Surg. 2009;19(5):641–644.
29. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology. 2001;120:669–681.
30. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518-25.
31. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 2009;32:514-20.
32. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995;80:364-9.
33. Letiexhe MR, Desaive C, Lefèbvre PJ, Scheen AJ. Intact cross-talk between insulin secretion and insulin action after post-gastroplasty recovery of ideal body weight in severely obese patients. Int J Obesity 2004;28:821-3.
34. Kadera BE, Lum K, Grant J, Pryor AD, Portenier DD, DeMaria EJ. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis 2009;5:305-9.
35. Lin E. Davis SS, Srinivasan J, Sweeney JF, Ziegler TR, Phillips L, Gletsu-Miller N. Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass. Am Surg 2009;75:498-502.

36. Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes 2009;33(Suppl 1):S33-40.
37. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009;52:2270-6.
38. Brancatisano A, Wahlroos S, Matthews S, Brancatisano R. Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. Surg Obes Relat Dis 2008;4:423-9.
39. Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab 1998;23:116-23.